K-Stem Cell’s ‘Placenta Stem Cell Cultivation Technology’ patented in Japan and Singapore

K-Stem Cell, Co., Ltd., a bio company specializing in adult stem cells, announced on the 15th that it received the notification of patent registration of its “Culture media and methods for culturing mesenchymal stem cell” from Japan and Singapore (Application No. in Japan: 2013-52064; Application No. in Singapore: 201300377-7).

This technology relates to culture medium for cultivation of mesenchymal stem cells. It is capable of maintaining the differentiating ability during cultivation, while enhancing the cells’ proliferating ability. This technology allows for rapidly acquiring mesenchymal stem cells required for stem cell treatment, while enhancing the differentiating ability of mesenchymal stem cells.

It has been patented in six countries including South Korea, US, China and Europe. With the patent registration in Japan, the company has gained technological advantages for stem cell technologies in South Korea as well as Japan. In addition, the placenta stem cell storage bank business, the main throng of Biostar’s business efforts, will finally hit its stride.

Biostar, a comprehensive stem cell bank founded using its core patents and technologies related with placenta-derived stem cells, is the only stem cell bank in the world to operate a system which cultures and stores stem cells using its unparalleled adult stem cell cultivation technology.

Placenta is a tissue during pregnancy. It helps the embryo to grow, functions as the embryo’s underdeveloped heart, lungs, liver and kidneys, and prevents harmful substances from entering the system. Compared with cord blood, one thousand times more mesenchymal stem cells can be acquired from placenta. Placental stem cells also offer the benefit of low possibility of immunorejection. Therefore, they can be used by the person from which the cells are collected, as well as his/her immediate family members.

The patent registration in Japan is expected to boost the stem cell cultivation/supply business of R-Japan, a Nature Cell affiliate. In addition, the patent registration in Singapore, the bridgehead into South Asia, will help the company to enter the South Asian market.

Deputy Director Won-geun Kang expressed his aspiration, saying “we will do our best to make Biostar’s stem cell technologies the global standard.”